Promising combo targets tough cancers in early trial
NCT ID NCT03049618
First seen Nov 01, 2025 · Last updated May 14, 2026 · Updated 32 times
Summary
This study tested a combination of two drugs—sEphB4-HSA and pembrolizumab—in 42 people with advanced non-small cell lung cancer or head/neck cancer that had spread or returned. The goal was to see if the combo could shrink tumors better than standard treatments. Participants had already tried chemotherapy or other targeted therapies. The trial measured how many patients responded and tracked side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT HEAD AND NECK CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
USC / Norris Comprehensive Cancer Center
Los Angeles, California, 90033, United States
Conditions
Explore the condition pages connected to this study.